The abstract is read at the publisher; the summary is JClub's.
In high-risk atrial fibrillation patients from two randomized trials (1,290 participants), percutaneous left atrial appendage closure showed no statistically significant difference vs medical therapy for stroke/systemic embolism/cardiovascular death (adjusted HR 0.98).
- Why it matters: Clinicians need evidence on whether left atrial appendage closure improves efficacy or safety compared with contemporary medical therapy in patients simultaneously at high risk of stroke and bleeding, where uncertainty remains.
- What they did: Individual participant data from CLOSURE-AF and PRAGUE-17 were analyzed using Cox models stratified by trial and adjusted for age, sex, CHA2DS2-VASc, and HAS-BLED; efficacy used time to first stroke/systemic embolism/cardiovascular/unknown death, and safety used time to first major bleeding with a time-varying Cox approach.
- The result: Primary efficacy occurred in 21.9% vs 20.7% (adjusted HR 0.98; P=0.842) and major bleeding in 13.3% vs 12.4% (adjusted HR 1.03; P=0.874), with major bleeding hazard varying over time but no cumulative bleeding benefit by 3 years (13.2% vs 12.1%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.